These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

182 related articles for article (PubMed ID: 30132075)

  • 1. The structure of the human glutaminyl cyclase-SEN177 complex indicates routes for developing new potent inhibitors as possible agents for the treatment of neurological disorders.
    Pozzi C; Di Pisa F; Benvenuti M; Mangani S
    J Biol Inorg Chem; 2018 Dec; 23(8):1219-1226. PubMed ID: 30132075
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Human glutaminyl cyclase: Structure, function, inhibitors and involvement in Alzheimer's disease.
    Vijayan DK; Zhang KYJ
    Pharmacol Res; 2019 Sep; 147():104342. PubMed ID: 31288079
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The soluble Y115E-Y117E variant of human glutaminyl cyclase is a valid target for X-ray and NMR screening of inhibitors against Alzheimer disease.
    DiPisa F; Pozzi C; Benvenuti M; Andreini M; Marconi G; Mangani S
    Acta Crystallogr F Struct Biol Commun; 2015 Aug; 71(Pt 8):986-92. PubMed ID: 26249687
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Inhibitors for human glutaminyl cyclase by structure based design and bioisosteric replacement.
    Buchholz M; Hamann A; Aust S; Brandt W; Böhme L; Hoffmann T; Schilling S; Demuth HU; Heiser U
    J Med Chem; 2009 Nov; 52(22):7069-80. PubMed ID: 19863057
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Structure-activity relationships of benzimidazole-based glutaminyl cyclase inhibitors featuring a heteroaryl scaffold.
    Ramsbeck D; Buchholz M; Koch B; Böhme L; Hoffmann T; Demuth HU; Heiser U
    J Med Chem; 2013 Sep; 56(17):6613-25. PubMed ID: 23886302
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Structures of glycosylated mammalian glutaminyl cyclases reveal conformational variability near the active center.
    Ruiz-Carrillo D; Koch B; Parthier C; Wermann M; Dambe T; Buchholz M; Ludwig HH; Heiser U; Rahfeld JU; Stubbs MT; Schilling S; Demuth HU
    Biochemistry; 2011 Jul; 50(28):6280-8. PubMed ID: 21671571
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Identifying hQC Inhibitors of Alzheimer's Disease by Effective Customized Pharmacophore-Based Virtual Screening, Molecular Dynamic Simulation, and Binding Free Energy Analysis.
    Lin W; Zheng X; Fang D; Zhou S; Wu W; Zheng K
    Appl Biochem Biotechnol; 2019 Apr; 187(4):1173-1192. PubMed ID: 30187344
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Probing secondary glutaminyl cyclase (QC) inhibitor interactions applying an in silico-modeling/site-directed mutagenesis approach: implications for drug development.
    Koch B; Buchholz M; Wermann M; Heiser U; Schilling S; Demuth HU
    Chem Biol Drug Des; 2012 Dec; 80(6):937-46. PubMed ID: 22967026
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Glutaminyl Cyclase Inhibitor PQ912 Improves Cognition in Mouse Models of Alzheimer's Disease-Studies on Relation to Effective Target Occupancy.
    Hoffmann T; Meyer A; Heiser U; Kurat S; Böhme L; Kleinschmidt M; Bühring KU; Hutter-Paier B; Farcher M; Demuth HU; Lues I; Schilling S
    J Pharmacol Exp Ther; 2017 Jul; 362(1):119-130. PubMed ID: 28446518
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pharmacophore-driven identification of human glutaminyl cyclase inhibitors from foods, plants and herbs unveils the bioactive property and potential of Azaleatin in the treatment of Alzheimer's disease.
    Tsai KC; Zhang YX; Kao HY; Fung KM; Tseng TS
    Food Funct; 2022 Dec; 13(24):12632-12647. PubMed ID: 36416361
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Synthesis and Evaluation of Diphenyl Conjugated Imidazole Derivatives as Potential Glutaminyl Cyclase Inhibitors for Treatment of Alzheimer's Disease.
    Li M; Dong Y; Yu X; Li Y; Zou Y; Zheng Y; He Z; Liu Z; Quan J; Bu X; Wu H
    J Med Chem; 2017 Aug; 60(15):6664-6677. PubMed ID: 28700245
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Potent human glutaminyl cyclase inhibitors as potential anti-Alzheimer's agents: Structure-activity relationship study of Arg-mimetic region.
    Ngo VTH; Hoang VH; Tran PT; Ann J; Cui M; Park G; Choi S; Lee J; Kim H; Ha HJ; Choi K; Kim YH; Lee J
    Bioorg Med Chem; 2018 Mar; 26(5):1035-1049. PubMed ID: 29398442
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Discovery of highly potent human glutaminyl cyclase (QC) inhibitors as anti-Alzheimer's agents by the combination of pharmacophore-based and structure-based design.
    Van Manh N; Hoang VH; Ngo VTH; Ann J; Jang TH; Ha JH; Song JY; Ha HJ; Kim H; Kim YH; Lee J; Lee J
    Eur J Med Chem; 2021 Dec; 226():113819. PubMed ID: 34536669
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Exploring the binding mode of PQ912 against secretory glutaminyl cyclase through systematic exploitation of conformational ensembles.
    Chandran R; Dileep KV
    Chem Biol Drug Des; 2021 Nov; 98(5):850-856. PubMed ID: 34423556
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Amyloidogenic processing of amyloid precursor protein: evidence of a pivotal role of glutaminyl cyclase in generation of pyroglutamate-modified amyloid-beta.
    Cynis H; Scheel E; Saido TC; Schilling S; Demuth HU
    Biochemistry; 2008 Jul; 47(28):7405-13. PubMed ID: 18570439
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Inhibitory effect of flavonoids on human glutaminyl cyclase.
    Li M; Dong Y; Yu X; Zou Y; Zheng Y; Bu X; Quan J; He Z; Wu H
    Bioorg Med Chem; 2016 May; 24(10):2280-6. PubMed ID: 27061673
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Glutaminyl cyclase inhibition attenuates pyroglutamate Abeta and Alzheimer's disease-like pathology.
    Schilling S; Zeitschel U; Hoffmann T; Heiser U; Francke M; Kehlen A; Holzer M; Hutter-Paier B; Prokesch M; Windisch M; Jagla W; Schlenzig D; Lindner C; Rudolph T; Reuter G; Cynis H; Montag D; Demuth HU; Rossner S
    Nat Med; 2008 Oct; 14(10):1106-11. PubMed ID: 18836460
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Discovery of potent indazole-based human glutaminyl cyclase (QC) inhibitors as Anti-Alzheimer's disease agents.
    Van Manh N; Hoang VH; Ngo VTH; Kang S; Jeong JJ; Ha HJ; Kim H; Kim YH; Ann J; Lee J
    Eur J Med Chem; 2022 Dec; 244():114837. PubMed ID: 36265279
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Crystal structures of human glutaminyl cyclase, an enzyme responsible for protein N-terminal pyroglutamate formation.
    Huang KF; Liu YL; Cheng WJ; Ko TP; Wang AH
    Proc Natl Acad Sci U S A; 2005 Sep; 102(37):13117-22. PubMed ID: 16135565
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Hydrazides Are Potent Transition-State Analogues for Glutaminyl Cyclase Implicated in the Pathogenesis of Alzheimer's Disease.
    Kupski O; Funk LM; Sautner V; Seifert F; Worbs B; Ramsbeck D; Meyer F; Diederichsen U; Buchholz M; Schilling S; Demuth HU; Tittmann K
    Biochemistry; 2020 Jul; 59(28):2585-2591. PubMed ID: 32551535
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.